Selected publications

Publications

  1. Gelfo, V.; Pontis, F.; Mazzeschi, M.; Sgarzi, M.; Mazzarini, M.; Solmi, R.; D’Uva, G.; Lauriola, M. Glucocorticoid Receptor Modulates EGFR Feedback upon Acquisition of Resistance to Monoclonal Antibodies. J. Clin. Med. 2019, doi:10.3390/jcm8050600.
  2. Gelfo, V.; Mazzeschi, M.; Grilli, G.; Lindzen, M.; Santi, S.; D’Uva, G.; Győrffy, B.; Ardizzoni, A.; Yarden, Y.; Lauriola, M. A Novel Role for the Interleukin-1 Receptor Axis in Resistance to Anti-EGFR Therapy. Cancers (Basel). 2018, doi:10.3390/cancers10100355.
  3. Roth, L.; Srivastava, S.; Lindzen, M.; Sas-Chen, A.; Sheffer, M.; Lauriola, M.; Enuka, Y.; Noronha, A.; Mancini, M.; Lavi, S.; Tarcic, G.; Pines, G.; Nevo, N.; Heyman, O.; Ziv, T.; Rueda, O. M.; Gnocchi, D.; Pikarski, E.; Admon, A.; Caldas, C.; Yarden, Y. SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Sci. Signal. 2018, 11, doi:10.1126/scisignal.aan0949.
  4. Rodia, M. T.; Solmi, R.; Pasini, F.; Nardi, E.; Mattei, G.; Ugolini, G.; Ricciardiello, L.; Strippoli, P.; Miglio, R.; Lauriola, M. LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result. Clin. Colorectal Cancer 2017, doi:10.1016/j.clcc.2017.12.002.
  5. Enuka, Y.; Feldman, M. E.; Chowdhury, A.; Srivastava, S.; Lindzen, M.; Sas-Chen, A.; Massart, R.; Cheishvili, D.; Suderman, M. J.; Zaltsman, Y.; Mazza, C. A.; Shukla, K.; Körner, C.; Furth, N.; Lauriola, M.; Oren, M.; Wiemann, S.; Szyf, M.; Yarden, Y. Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone. Nucleic Acids Res. 2017, doi:10.1093/nar/gkx865.
  6. Gelfo, V.; Rodia, M. T.; Pucci, M.; Dall’Ora, M.; Santi, S.; Solmi, R.; Roth, L.; Lindzen, M.; Bonafè, M.; Bertotti, A.; Caramelli, E.; Lollini, P.; Trusolino, L.; Yarden, Y.; D’Uva, G.; Lauriola, M. A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. Oncotarget 2016, doi:10.18632/oncotarget.12354.
  7. Rodia, M. T.; Ugolini, G.; Mattei, G.; Montroni, I.; Zattoni, D.; Ghignone, F.; Veronese, G.; Marisi, G.; Lauriola, M.; Strippoli, P.; Solmi, R. Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget 2016, doi:10.18632/oncotarget.8108.
  8. Li, Y.; Lauriola, M.; Kim, D.; Francesconi, M.; D’Uva, G.; Shibata, D.; Malafa, M. P.; Yeatman, T. J.; Coppola, D.; Solmi, R.; Cheng, J. Q. Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancer. Oncogene 2016, 35, 4558–4568, doi:10.1038/onc.2015.522.
  9. D’Uva, G.; Lauriola, M. Towards the emerging crosstalk: ERBB family and steroid hormones. Semin. Cell Dev. Biol. 2016, 50, 143–152, doi:10.1016/j.semcdb.2015.11.004.
  10. D’Uva, G.; Lauriola, M. Shaping ERBB Signalling by Steroid Hormones. J Steroids Horm. Sci 2016, 7, 2.
  11. Enuka, Y.; Lauriola, M.; Feldman, M. E.; Sas-Chen, A.; Ulitsky, I.; Yarden, Y. Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Res. 2016, 44, 1370–83, doi:10.1093/nar/gkv1367.
  12. D’Uva, G.; Aharonov, A.; Lauriola, M.; Kain, D.; Yahalom-Ronen, Y.; Carvalho, S.; Weisinger, K.; Bassat, E.; Rajchman, D.; Yifa, O.; Lysenko, M.; Konfino, T.; Hegesh, J.; Brenner, O.; Neeman, M.; Yarden, Y.; Leor, J.; Sarig, R.; Harvey, R. P.; Tzahor, E. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol. 2015, 17, 627–638, doi:10.1038/ncb3149.
  13. Carvalho, S.; Lindzen, M.; Lauriola, M.; Shirazi, N.; Sinha, S.; Abdul-Hai, a; Levanon, K.; Korach, J.; Barshack, I.; Cohen, Y.; Onn,  a; Mills, G.; Yarden, Y. An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors. Oncogene 2015, 35, 1–10, doi:10.1038/onc.2015.93.
  14. Kedmi, M.; Ben-Chetrit, N.; Körner, C.; Mancini, M.; Ben-Moshe, N. B.; Lauriola, M.; Lavi, S.; Biagioni, F.; Carvalho, S.; Cohen-Dvashi, H.; Schmitt, F.; Wiemann, S.; Blandino, G.; Yarden, Y. EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Sci. Signal. 2015, 8, ra29-ra29.
  15. Cohen-Dvashi, H.; Ben-Chetrit, N.; Russell, R.; Carvalho, S.; Lauriola, M.; Nisani, S.; Mancini, M.; Nataraj, N.; Kedmi, M.; Roth, L.; Köstler, W.; Zeisel, A.; Yitzhaky, A.; Zylberg, J.; Tarcic, G.; Eilam, R.; Wigelman, Y.; Will, R.; Lavi, S.; Porat, Z.; Wiemann, S.; Ricardo, S.; Schmitt, F.; Caldas, C.; Yarden, Y. Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO Mol. Med. 2015, 7, 299–314, doi:10.15252/emmm.201404134.
  16. Ben-Chetrit, N.; Chetrit, D.; Russell, R.; Korner, C.; Mancini, M.; Abdul-Hai, A.; Itkin, T.; Carvalho, S.; Cohen-Dvashi, H.; Koestler, W. J.; Shukla, K.; Lindzen, M.; Kedmi, M.; Lauriola, M.; Shulman, Z.; Barr, H.; Seger, D.; Ferraro, D. A.; Pareja, F.; Gil-Henn, H.; Lapidot, T.; Alon, R.; Milanezi, F.; Symons, M.; Ben-Hamo, R.; Efroni, S.; Schmitt, F.; Wiemann, S.; Caldas, C.; Ehrlich, M.; Yarden, Y. Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Sci. Signal. 2015, 8, ra7, doi:10.1126/scisignal.2005537.
  17. Lauriola, M.; Enuka, Y.; Zeisel, A.; D’Uva, G.; Roth, L.; Sharon-Sevilla, M.; Lindzen, M.; Sharma, K.; Nevo, N.; Feldman, M.; Carvalho, S.; Cohen-Dvashi, H.; Kedmi, M.; Ben-Chetrit, N.; Chen, A.; Solmi, R.; Wiemann, S.; Schmitt, F.; Domany, E.; Yarden, Y. Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nat. Commun. 2014, 5, 5073, doi:10.1038/ncomms6073.
  18. Peña-Altamira, E.; Polazzi, E.; Moretto, E.; Lauriola, M.; Monti, B. The transcription factor CCAAT enhancer-binding protein β protects rat cerebellar granule neurons from apoptosis through its transcription-activating isoforms. Eur. J. Neurosci. 2014, 39, 176–185.
  19. Zeisel, A.; Yitzhaky, A.; Koerner, C.; Lauriola, M.; Cohen-Dvashi, H.; Köstler, W. J.; Yarden, Y.; Wiemann, S.; Domany, E. qCMA: a desktop application for quantitative collective cell migration analysis. J. Biomol. Screen. 2013, 18, 356–60.
  20. D’Uva, G.; Bertoni, S.; Lauriola, M.; De Carolis, S.; Pacilli, A.; D’Anello, L.; Santini, D.; Taffurelli, M.; Ceccarelli, C.; Yarden, Y.; Montanaro, L.; Bonafé, M.; Storci, G. Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS One 2013, 8, e80742, doi:10.1371/journal.pone.0080742.
  21. Pradeep, C.-R. C.-R.; Zeisel, A.; Köstler, W. J. J.; Lauriola, M.; Jacob-Hirsch, J.; Haibe-Kains, B.; Amariglio, N.; Ben-Chetrit, N.; Emde, A.; Solomonov, I.; Neufeld, G.; Piccart, M.; Sagi, I.; Sotiriou, C.; Rechavi, G.; Domany, E.; Desmedt, C.; Yarden, Y. Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene 2012, 31, 3569–83, doi:10.1038/onc.2011.547.
  22. Pradeep, C.-R. C.-R.; Köstler, W. J. J.; Lauriola, M.; Granit, R. Z. Z.; Zhang, F.; Jacob-Hirsch, J.; Rechavi, G.; Nair, H. B. B.; Hennessy, B. T. T.; Gonzalez-Angulo, A. M. M.; Tekmal, R. R. R.; Ben-Porath, I.; Mills, G. B. B.; Domany, E.; Yarden, Y. Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene 2012, 31, 907–17, doi:10.1038/onc.2011.279.
  23. Zwang, Y.; Sas-Chen, A.; Drier, Y.; Shay, T.; Avraham, R.; Lauriola, M.; Shema, E.; Lidor-Nili, E.; Jacob-Hirsch, J.; Amariglio, N.; Lu, Y.; Mills, G. B.; Rechavi, G.; Oren, M.; Domany, E.; Yarden, Y. Two Phases of Mitogenic Signaling Unveil Roles for p53 and EGR1 in Elimination of Inconsistent Growth Signals. Mol. Cell 2011, 42, 524–535.
  24. Martinelli, M.; Pacilli, A. M. G.; Rivetti, S.; Lauriola, M.; Fasano, L.; Carbonara, P.; Mattei, G.; Valentini, I.; Scapoli, L.; Solmi, R. A role for epidermal growth factor receptor in idiopathic pulmonary fibrosis onset. Mol. Biol. Rep. 2011, 38, 4613–4617.
  25. Rivetti, S, Lauriola, M., Voltattorni, M, Bianchini, M, Martini, D, Ceccarelli, C, Palmieri, A, Mattei, G., Franchi, M., Ugolini, G, Rosati, G., Montroni, I, Taffurelli, M., Solmi, R. Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant. Int. J. Immunopathol. Pharmacol. 2011, 24, 639–649.
  26. Lauriola, M.; Ugolini, G.; Rivetti, S.; Nan??, S.; Rosati, G.; Zanotti, S.; Montroni, I.; Manaresi, A.; Zattoni, D.; Belluzzi, A.; Castellani, L.; D’Uva, G.; Mattei, G.; Taffurelli, M.; Strippoli, P.; Solmi, R. IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn’s disease and correlation with sub-phenotypes. Int. J. Mol. Med. 2011, 27, 469–477, doi:10.3892/ijmm.2010.591.
  27. Lauriola, M.; Ugolini, G.; Rosati, G.; Zanotti, S.; Montroni, I.; Manaresi, A.; Zattoni, D.; Rivetti, S.; Mattei, G.; Coppola, D.; Strippoli, P.; Taffurelli, M.; Solmi, R. Identification by a Digital Gene Expression Displayer (DGED) and test by RT-PCR analysis of new mRNA candidate markers for colorectal cancer in peripheral blood. Int. J. Oncol. 2010, 37, 519–525.
  28. Martinelli, M.; Ugolini, G.; Scapoli, L.; Rivetti, S.; Lauriola, M.; Mattei, G.; Rosati, G.; Montroni, I.; Manaresi, A.; Zattoni, D.; Taffurelli, M.; Solmi, R. The EGFR R521K polymorphism influences the risk to develop colorectal cancer. Cancer Biomarkers 2010, 8, 61–65.
  29. Solmi, R.; Lauriola, M.; Francesconi, M.; Martini, D.; Voltattorni, M.; Ceccarelli, C.; Ugolini, G.; Rosati, G.; Zanotti, S.; Montroni, I.; Mattei, G.; Taffurelli, M.; Santini, D.; Pezzetti, F.; Ruggeri, A.; Castellani, G.; Guidotti, L.; Coppola, D.; Strippoli, P. Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer 2008, 8, 227.
  30. Solmi, R.; Ugolini, G.; Rosati, G.; Zanotti, S.; Lauriola, M.; Montroni, I.; del Governatore, M.; Caira, A.; Taffurelli, M.; Santini, D.; Coppola, D.; Guidotti, L.; Carinci, P.; Strippoli, P. Microarray-based identification and RT-PCR test screening for epithelial-specific mRNAs in peripheral blood of patients with colon cancer. BMC Cancer 2006, 6, 250, doi:10.1186/1471-2407-6-250.

Roth L, Lindzen, Sas-Chen A, Noronha A, Sheffer M, Mancini M, Enuka Y, Tarcic G, Pines G, Lauriola M, Nevo N, Porat Z, Sevilla-Sharon M, Carvalho S, Ziv T, Domany E, Admon E, Caldas C and Yarden Y. (2018).SILAC identifies LAD1 as a filamin-binding regulator of actin dynamics in response to EGF and a marker of aggressive breast tumors. Science Signaling 2018.

Rodia MT, Solmi R, Pasini F, Nardi E, Mattei G, Ugolini GP, Ricciardiello L, Strippoli PL, Miglio R, Lauriola M (2018). LGALS4, CEACAM6, TSPAN8, and COL1A2: Blood Markers for Colorectal Cancer-Validation in a Cohort of Subjects With Positive Fecal Immunochemical Test Result.  Clin Colorectal Cancer. 2017 Dec 12

Enuka Y, Feldman ME, Chowdhury A, Srivastava S, Lindzen M, Sas-Chen A, Massart R, Cheishvili D, Suderman MJ, Zaltsman Y, Mazza CA, Shukla K, Körner C, Furth N, Lauriola M, Oren M, Wiemann S, Szyf M, Yarden Y. (2017). Epigenetic mechanisms underlie the crosstalk between growth factors and a steroid hormone. Nucleic Acids Res. 2017 Dec 15;45(22):12681-12699. doi: 10.1093/nar/gkx865.

Gelfo, V., Rodia, M. T., Pucci, M., Dall’Ora, M., Santi, S., Solmi, R., Lauriola, M. (2016).
A module of inflammatory cytokines defines resistance of colorectal cancer to EGFR inhibitors. Oncotarget. https://doi.org/10.18632/oncotarget.12354

Li, Y., Lauriola, M., Kim, D., Francesconi, M., D’Uva, G., Shibata, D., … Cheng, J. Q. (2016).Adenomatous polyposis coli (APC) regulates miR17-92 cluster through β-catenin pathway in colorectal cancer. Oncogene, 35(35), 4558–4568. https://doi.org/10.1038/onc.2015.522

D’Uva, G., & Lauriola, M. (2016).
Shaping ERBB Signalling by Steroid Hormones. J Steroids Hormon Sci, 7(1000.166), 2.

Rodia, M. T., Ugolini, G., Mattei, G., Montroni, I., Zattoni, D., Ghignone, F., … Solmi, R. (2016).Systematic large-scale meta-analysis identifies a panel of two mRNAs as blood biomarkers for colorectal cancer detection. Oncotarget. https://doi.org/10.18632/oncotarget.8108

Carvalho, S., Lindzen, M., Lauriola, M., Shirazi, N., Sinha, S., Abdul-Hai, a, … Yarden, Y. (2015).An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors. Oncogene, 35(October 2014), 1–10. https://doi.org/10.1038/onc.2015.93

Enuka, Y., Lauriola, M., Feldman, M. E., Sas-Chen, A., Ulitsky, I., & Yarden, Y. (2015).Circular RNAs are long-lived and display only minimal early alterations in response to a growth factor. Nucleic Acids Research, gkv1367-. https://doi.org/10.1093/nar/gkv1367

Kedmi, M., Ben-Chetrit, N., Körner, C., Mancini, M., Ben-Moshe, N. B., Lauriola, M.,Yarden, Y. (2015).EGF induces microRNAs that target suppressors of cell migration: miR-15b targets MTSS1 in breast cancer. Science Signaling, 8(368), ra29-ra29.

D’Uva, G., Aharonov, A., Lauriola, M., Kain, D., Yahalom-Ronen, Y., Carvalho, S., … Tzahor, E. (2015).ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nature Cell Biology, 17(5), 627–638.

Cohen-Dvashi, H., Ben-Chetrit, N., Russell, R., Carvalho, S., Lauriola, M., Nisani, S., … Yarden, Y. (2015).Navigator-3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO Molecular Medicine, 7(3), 299–314. https://doi.org/10.15252/emmm.201404134

Ben-Chetrit, N., Chetrit, D., Russell, R., Korner, C., Mancini, M., Abdul-Hai, A., … Yarden, Y. (2015).Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer. Science Signaling, 8(360), ra7. https://doi.org/10.1126/scisignal.2005537

D’Uva, G., & Lauriola, M. (2015).
Towards the emerging crosstalk: ERBB family and steroid hormones. Seminars in Cell and Developmental Biology. Academic Press.

Lauriola, M., Enuka, Y., Zeisel, A., D’Uva, G., Roth, L., Sharon-Sevilla, M., … Yarden, Y. (2014).Diurnal suppression of EGFR signalling by glucocorticoids and implications for tumour progression and treatment. Nature Communications, 5, 5073.

Peña-Altamira, E., Polazzi, E., Moretto, E., Lauriola, M., & Monti, B. (2014).
The transcription factor CCAAT enhancer-binding protein β protects rat cerebellar granule neurons from apoptosis through its transcription-activating isoforms. European Journal of Neuroscience, 39(2), 176–185.

D’Uva, G., Bertoni, S., Lauriola, M., De Carolis, S., Pacilli, A., D’Anello, L.,Storci, G. (2013).Beta-catenin/HuR post-transcriptional machinery governs cancer stem cell features in response to hypoxia. PLoS ONE, 8(11).

Zeisel, A., Yitzhaky, A., Koerner, C., Lauriola, M., Cohen-Dvashi, H., Köstler, W. J., … Domany, E. (2013).qCMA: a desktop application for quantitative collective cell migration analysis. Journal of Biomolecular Screening, 18(3), 356–60.

Pradeep, C.-R., Köstler, W. J., Lauriola, M., Granit, R. Z., Zhang, F., Jacob-Hirsch, J., … Yarden, Y. (2012).
Modeling ductal carcinoma in situ: a HER2-Notch3 collaboration enables luminal filling. Oncogene, 31(7), 907–17. https://doi.org/10.1038/onc.2011.279

Pradeep, C.-R., Zeisel, A., Köstler, W. J., Lauriola, M., Jacob-Hirsch, J., Haibe-Kains, B., … Yarden, Y. (2012).
Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions. Oncogene, 31(31), 3569–83. https://doi.org/10.1038/onc.2011.547

Rivetti, S, Lauriola, M., Voltattorni, M, Bianchini, M, Martini, D, Ceccarelli, C, Palmieri, A, Mattei, G., Franchi, M., Ugolini, G, Rosati, G., Montroni, I, Taffurelli, M., Solmi, R. (2011).
Gene expression profile of human colon cancer cells treated with cross-reacting material 197, a diphtheria toxin non-toxic mutant. International Journal of Immunopathology and Pharmacology, 24(3), 639–649.

Lauriola, M., Ugolini, G., Rivetti, S., Nan??, S., Rosati, G., Zanotti, S., … Solmi, R. (2011).IL23R, NOD2/CARD15, ATG16L1 and PHOX2B polymorphisms in a group of patients with Crohn’s disease and correlation with sub-phenotypes..International Journal of Molecular Medicine, 27(3), 469–477. https://doi.org/10.3892/ijmm.2010.591

Zwang, Y., Sas-Chen, A., Drier, Y., Shay, T., Avraham, R., Lauriola, M., … Yarden, Y. (2011).Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals. Molecular Cell, 42(4), 524–535.

Lauriola, M., Ugolini, G., Rosati, G., Zanotti, S., Montroni, I., Manaresi, A., … Solmi, R. (2010).Identification by a Digital Gene Expression Displayer (DGED) and test by RT-PCR analysis of new mRNA candidate markers for colorectal cancer in peripheral blood. International Journal of Oncology, 37(2), 519–525.

Solmi, R., Lauriola, M., Francesconi, M., Martini, D., Voltattorni, M., Ceccarelli, C., … Strippoli, P. (2008).Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines. BMC Cancer, 8, 227.

Proudly powered by WordPress